North American Pharmacal, Inc. – Trademark Portfolio
Entity Type: 03
North American Pharmacal, Inc. holds 31 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 30 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 2 Nice Classification classes. Currently, 13 trademarks are registered. Notable registered marks include ARA 6, UNIBAR, DEFLECT, CATECHOL, and POLYVITE. The owner is based in Norwalk, CT.
149 Water Street
First Floor
Norwalk, CT 06854
Showing of trademarks Trademarks
Trademark Classifications
North American Pharmacal, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does North American Pharmacal, Inc. have?
North American Pharmacal, Inc. has 31 U.S. trademarks filed with the USPTO. Of these, 13 registered, 12 abandoned, 6 cancelled.
What trademark classes does North American Pharmacal, Inc. file in?
North American Pharmacal, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are North American Pharmacal, Inc.'s most well-known trademarks?
North American Pharmacal, Inc.'s registered trademark portfolio includes well-known marks such as ARA 6, UNIBAR, DEFLECT, CATECHOL, and POLYVITE. These are among 13 currently registered trademarks in the portfolio.
What is North American Pharmacal, Inc.'s trademark registration success rate?
North American Pharmacal, Inc. has a 42% trademark registration rate, with 13 out of 31 resolved applications resulting in successful registration. Currently, 0 applications are pending review.